Radiopharm Theranostics Ltd ADR RADX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.28
- Day Range
- $4.20–4.42
- 52-Week Range
- $3.62–16.25
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 7.88M
- Market Cap
- $33.82M
- Volume/Avg
- 35,099 / 30,250
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 14
Valuation
|
Metric
|
RADX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.19 |
Price/Sales | 13.07 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RADX
|
|---|---|
Quick Ratio | 2.65 |
Current Ratio | 2.67 |
Interest Coverage | −598.19 |
Quick Ratio
RADX
Profitability
|
Metric
|
RADX
|
|---|---|
Return on Assets (Normalized) | −40.84% |
Return on Equity (Normalized) | −81.27% |
Return on Invested Capital (Normalized) | −56.22% |
Return on Assets
RADX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|YtMsD^< | LOCK|r!%@s | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|gwTbf$s | LOCK|#ns@ | $71B | |||
| argenx SE ADR
ARGX
| LOCK|tZSrW! | LOCK|&Q | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|KnQc@Z& | LOCK|Q#g | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|g&>QBgV | LOCK|FFnv$ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Y#C>&Nn | LOCK|zzJf | $26B | |||
| Moderna Inc
MRNA
| LOCK|r?&cg^f | LOCK|#!% | $25B | |||
| Incyte Corp
INCY
| LOCK|w&s$<l | LOCK|vHT | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Z#K%>#> | LOCK|xg | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|hSD$@kJ | LOCK|qt | $16B |
United States